Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial

AIMS: To investigate efficacy and safety of the sodium–glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin administered as add‐on therapy to the dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: We conducted a multice...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Iijima, Hiroaki, Watanabe, Yumi, Gouda, Maki
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484989/
https://ncbi.nlm.nih.gov/pubmed/28177187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12898
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados